In Vitro | Kinase Assay: For selectivity profiling experiments, the lysates (5 mg of total protein each) are preincubated with 0 (DMSO control), 2.5 nM, 25 nM, 250 nM, 2.5 μM or 25 μM free compound (GSK690693 or GSK2141795) on an end-over-end shaker for 45 min at 4°C. Subsequently, lysates are incubated with beads (coupled Akt probe or kinobeads) for 1 h at 4°C, for both qualitative and quantitative experiments. The beads are washed with 1×CP buffer and collected by centrifugation. Bound proteins are eluted with 2×NuPAGE LDS sample buffer, and eluates are reduced and alkylated by 50 mM dithiothreitol and 55 mM iodoacetamide.
Cell Assay: Cells were washed in ice-cold tris buffered saline (TBS), spun down and lysed in radioimmunoprecipitation assay buffer (10 mM Tris HCl, pH 8, 5 mM Na2EDTA, pH 8, 1% NP-40, 0.5% sodium dioxycholate, 0.1% SDS), both containing protease and phosphatase inhibitors (Complete Mini PhosphoSTOP, Roche, Basel, Switzerland). Protein concentrations were determined by Pierce BCA Protein Assay (Thermo Fisher Scientific, Rockford, IL, USA) according to the manufacturer’s protocol. 5–40 μg protein was resolved on 4–12% RunBlue SDS-PAGE gels (Expedeon, San Diego, CA, USA), transferred onto PVDF membrane (GE Healthcare Life Sciences, Buckinghamshire, UK), blocked and then incubated with primary monoclonal antibodies ON at 4 °C. Following, the membranes were incubated with goat anti-rabbit, goat anti-mouse (#P0448, #P0447, Dako, Glostrup, Denmark) or donkey anti-goat (#SC-2020, Santa Cruz Biotechnology, Heidelberg, Germany) HRP-conjugated secondary antibodies in 1:5000 dilution for 1 h at room temperature (RT). The immune reactive bands were visualized by Amersham ECL Prime Western Blotting Detecting Reagent (GE Healthcare Life Sciences) and exposed to CL-Xposure film (Thermo Fisher Scientific). |
---|
In Vivo | All animal experiments were approved by The Experimental Animal Committee of The Danish Ministry of Justice and were performed at the animal core facility at University of Southern Denmark. Mice were housed under pathogen-free conditions with ad libitum food and water. Subconfluent PC9-ER cells (1.5 x 106) were harvested using accutase and resuspended in a 1:1 mixture of extracellular matrix from Engelbreth-Holm-Swarm sarcoma (Sigma-Aldrich) and RPMI1640 media, and injected subcutaneously into 16-week-old female CB17 SCID mice (Taconic, Ejby, Denmark). When tumors reached a palpable diameter of 2–3 mm, mice were randomized into groups of n = 9 per group. Animals were euthanized if they showed any adverse signs of disease including weight loss, paralysis, thymus dysfunction, or general discomfort. Accordingly, eight mice were censored during the course of the study. Erlotinib HCl was formulated at 25 μg/g bodyweight in 15% Captisol (La Jolla, CA, USA). GSK2141795 was formulated at 10 μg/g bodyweight in DMSO. 15% Captisol was used as vehicle, and the concentration of DMSO did not exceed 10% when administered. Drugs were administered 5 days a week for 3 weeks by oral gavage. Maximum volume per mouse was 200 μL. Tumor volume and bodyweight were surveyed during the extent of the study. Tumor volume was measured with calipers and calculated according to: tumor volume (mm3) = (length×width2)/2. |
---|